LDN-212854

Overview

LDN-212854 is a bone morphogenetic protein ( BMP ) inhibitor that potently inhibits ALK2 ( IC 50 : 1.3 nM). LDN-212854 also inhibits ALK1 (IC 50 : 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-15897
• CAS No.: 1432597-26-6
• Molecular Formula: C25H22N6
• Molecular Weight: 406.48
• Purity: 99.62%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (6.15 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source